While Biogen gutted its commercial infrastructure for Alzheimer’s disease in a bid to save $1 billion a year, not all its work on Aduhelm is lost in the ramp up to its second bite at the apple with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results